Buy Dr Reddys Laboratories: target of Rs 1430: ICICI Securities
ICICI Securities reports Dr. Reddy's Laboratories (DRL) Q2FY27 EBITDA and PAT exceeded expectations by 32% and 26%, respectively. US sales grew 9.5% QoQ to $258 million, driven by new launches. Management expects double-digit revenue growth and gross margins of 50-55%. They aim for 25% EBITDA margins in the next few years, supported by upcoming catalysts like semaglutide relaunch and biosimilar approvals.
How this was made

The 30-second read
Why it matters
The earnings beat and raised guidance may attract short-covering and new buying, especially from investors focused on pharma growth in the US.
Market read
Strong Q2 results and forward outlook could drive DRR stock higher in the near term.
What to watch
Currency fluctuations and competitive pressure in the biosimilar space could temper upside.
Background
Dr Reddy's Laboratories (DRR) is a leading Indian generic drug maker with significant US market exposure.
Market effects
Boosts sentiment for Indian pharma and generic drug manufacturers.
Supports broader Indian market optimism on earnings season.
Highlights US market exposure for Indian pharma exporters.
Counterpoint
Potential concerns over execution risk of upcoming product launches and US regulatory approvals.
Key entities
- CompanyDr Reddy's Laboratories
Indian pharmaceutical company listed on NYSE (DRR).
- Research FirmICICI Securities
Provider of the earnings analysis and guidance.
